Subscribe

Jacobiopharma Details
Oct 10, 2019

Jacobio's original innovative drug JAB-3312 obtained NMPA new drug clinical trial permission

On September 29th, 2019, a small molecule oral anti-tumor drug JAB-3312, which was independently developed by Jacobio with global intellectual property rights, obtained clinical permission in China.

Source: Jacobiopharma